Aclasta IV Infusion

About Aclasta 5 mg/100 ml IV Infusion

Aclasta is a bisphosphonate medicine given as an intravenous infusion. It contains zoledronic acid and is used in the treatment of osteoporosis in adults, as prescribed by a doctor.

There are 2 brands of Zoledronic Acid [For osteoporosis] listed in Bangladesh. 1 of them has a lower unit price than Aclasta. The lowest listed price is Bonizol 5 mg/100 ml IV Infusion at ৳ 6000.00 per unit.

What is Aclasta 5 mg/100 ml IV Infusion?

Aclasta 5 mg/100 ml IV Infusion is a bisphosphonate preparation containing zoledronic acid. It is given by intravenous infusion in a healthcare setting, not taken by mouth. Bisphosphonates work on bone by reducing the action of cells that break down bone. Aclasta is prescribed for osteoporosis in adults, including postmenopausal women and men, and in some people using glucocorticoid medicines. The dose and how often it is given are decided by the doctor. The infusion is prepared and given by a healthcare professional.

Uses of Aclasta

Aclasta is used to treat osteoporosis in postmenopausal women, to reduce the chance of hip, spine and other fractures. It is also used after a hip fracture to prevent further clinical fractures, and to treat and prevent osteoporosis caused by glucocorticoid medicines. It is used in men with osteoporosis and in other osteoporosis treatment situations as the doctor decides. Only a doctor can confirm whether it is suitable for a particular person.

How to use Aclasta

Aclasta is given as an intravenous infusion by a healthcare professional; it is not for self-administration at home. The doctor decides the dose and the course. Patients are usually asked to drink enough fluid before and after the infusion. The infusion is prepared and given in a clinic or hospital where the patient can be monitored. Do not change or stop the schedule on your own; ask the doctor or pharmacist if you have questions about your treatment plan.

Side effects of Aclasta

After an infusion, some people get fever, muscle pain, joint pain, headache or flu-like symptoms. These mostly appear in the first few days and are often mild to moderate. Bone, joint or muscle pain has been reported uncommonly. Tell your doctor or pharmacist about any side effect that bothers you or does not go away. The doctor can advise on what can be done to ease post-dose symptoms. Seek medical help for severe symptoms.

Safety and precautions

Aclasta is not suitable for everyone. The doctor should be told about kidney problems, low blood calcium, eye problems such as uveitis, allergies to bisphosphonates, and pregnancy or breastfeeding. It is contraindicated in pregnancy and breastfeeding and is not recommended for children and adolescents. Good hydration is important before the infusion. Existing low calcium and other mineral problems need to be treated first. Always ask the doctor or pharmacist whether Aclasta is right for you and about any other medicines you take.

Frequently asked questions

How should Aclasta be stored?

Store Aclasta below 30°C before opening, and protect it from moisture and light. Keep it out of the reach and sight of children. Once it has been prepared for infusion, it is handled by the healthcare professional; ask them if you have any storage questions.

What is Aclasta used for and what kind of medicine is it?

Aclasta is a bisphosphonate medicine containing zoledronic acid. It is given by intravenous infusion for the treatment of osteoporosis in adults, including after a hip fracture and in glucocorticoid-related osteoporosis. The doctor decides if it is suitable for you.

Who should avoid Aclasta or ask the doctor first?

Tell the doctor if you are pregnant or breastfeeding, have kidney problems, low blood calcium, eye inflammation such as uveitis, or an allergy to bisphosphonates. It is not recommended for children and adolescents. Ask the doctor or pharmacist before treatment if any of these apply to you.

What is the price of Aclasta?

The listed price is ৳ 38190.00.

Indications

Aclasta is indicated in-
  • Treatment and prevention of postmenopausal osteoporosis
  • Treatment to increase bone mass in men with osteoporosis
  • Treatment and prevention of glucocorticoid-induced osteoporosis
  • Treatment of Paget's disease of bone in men and women
Limitations of Use: Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use.

Pharmacology

Zoledronic Acid is a bisphosphonate and acts primarily on bone. It is an inhibitor of osteoclast-mediated bone resorption. The selective action of bisphosphonates on bone is based on their high affinity for mineralized bone. Intravenously administered Zoledronic Acid rapidly partitions to bone and localizes preferentially at sites of high bone turnover. The main molecular target of Zoledronic Acid in the osteoclast is the enzyme farnesyl pyrophosphate synthase. The relatively long duration of action of Zoledronic Acid is attributable to its high binding affinity to bone mineral.

Dosage & Administration

Treatment of Osteoporosis in Postmenopausal Women: The recommended regimen is a 5 mg infusion once a year given intravenously over no less than 15 minutes.

Prevention of Osteoporosis in Postmenopausal Women: The recommended regimen is a 5 mg infusion given once every 2 years intravenously over no less than 15 minutes.

Osteoporosis in Men: The recommended regimen is a 5 mg infusion once a year given intravenously over no less than 15 minutes.

Treatment and Prevention of Glucocorticoid-Induced Osteoporosis: The recommended regimen is a 5 mg infusion once a year given intravenously over no less than 15 minutes.

Treatment of Paget’s Disease of Bone: The recommended dose is a 5 mg infusion. The infusion time must not be less than 15 minutes given over a constant infusion rate.

Re-treatment of Paget’s Disease: Re-treatment with Zoledronic Acid may be considered in patients who have relapsed, based on increases in serum alkaline phosphatase, or in those patients who failed to achieve normalization of their serum alkaline phosphatase, or in those patients with symptoms, as dictated by medical practice.

Calcium and Vitamin D Supplementation: Instruct patients being treated for Paget’s disease of bone on the importance of calcium and vitamin D supplementation in maintaining serum calcium levels, and on the symptoms of hypocalcemia. All patients should take 1500 mg elemental calcium daily in divided doses (750 mg two times a day, or 500 mg three times a day) and 800 international units vitamin D daily, particularly in the 2 weeks following Zoledronic Acid administration.

Instruct patients being treated for osteoporosis to take supplemental calcium and vitamin D if their dietary intake is inadequate. An average of at least 1200 mg calcium and 800-1000 international units vitamin D daily is recommended.

Interaction

Aminoglycosides: May lower serum calcium for prolonged periods.
Loop diuretics: May increase risk of hypocalcemia.
Nephrotoxic drugs: Use with caution.
Drugs primarily excreted by the kidney: Exposure may be increased with renal impairment. Monitor serum creatinine in patients at risk.

Contraindications

  • Hypocalcemia
  • Patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment
  • Hypersensitivity to any component of Zoledronic Acid

Side Effects

The most common adverse reactions (greater than 10%) were pyrexia, myalgia, headache, arthralgia, pain in extremity. Other important adverse reactions were flu-like illness, nausea, vomiting, diarrhea, and eye inflammation

Pregnancy & Lactation

Zoledronic Acid can cause fetal harm. Women of childbearing potential should be advised. Zoledronic Acid should not be given to nursing women.

Precautions & Warnings

  • Hypocalcemia may worsen during treatment. Patients must be adequately supplemented with calcium and vitamin D.
  • Renal Impairment: A single dose should not exceed 5 mg and the duration of infusion should be no less than 15 minutes. Renal toxicity may be greater in patients with underlying renal impairment or with other risk factors, including advanced age or dehydration. Monitor creatinine clearance before each dose.
  • Osteonecrosis of the Jaw (ONJ) has been reported. All patients should have a routine oral exam by the prescriber prior to treatment.
  • Atypical Femur Fractures have been reported. Patients with thigh or groin pain should be evaluated to rule out a femoral fracture.
  • Severe Bone, Joint, and Muscle Pain may occur. Withhold future doses of Aclasta if severe symptoms occur.

Overdose Effects

Patients who have received doses higher than those recommended should be carefully monitored. Over dosage may cause clinically significant renal impairment, hypocalcemia, hypophosphatemia, and hypomagnesemia. Clinically relevant reductions in serum levels of calcium, phosphorus, and magnesium should be corrected by intravenous administration of calcium gluconate, potassium or sodium phosphate, and magnesium sulfate, respectively. Single doses of Aclasta should not exceed 5 mg and the duration of the intravenous infusion should be no less than 15 minutes.

Storage Conditions

Store below 30° C prior to opening. Protect from moisture and light. Aclasta must be kept out of the reach and sight of children.

Alternative brands of Zoledronic Acid [For osteoporosis]

Other brands with the same generic name, cheapest first.

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.